Home Top Movers Here’s why Soligenix, Inc. (SNGX) stock is Popping High today

Here’s why Soligenix, Inc. (SNGX) stock is Popping High today

Soligenix, Inc. (SNGX) stock gained Pediatric Investigation Plan (PIP) waiver for HyBryte™ (SGX301 or hypericin) by European Medicines Agency (EMA) after which the SNGX stock price saw an uptrend of 10.26% to reach $1.29 a share at the time of this writing. The stock went high in the previous trading session following the receival of $865,000in non-dilutive funding news and closed with a 4.46% gain. Let’s discuss more about SNGX stock.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What’s Happening?

The Pediatric Investigation Plan waiver is for HyBryte™ which had been evaluated against early-stage cutaneous T-cell lymphoma(CTCL) in phase three clinical study. The phase three study has been successfully concluded recently. This Achievement will pace up the marketing approval process of Soligenix’s application across the globe. Soligenix management is looking forward to marketing approval as well as commercialization of HyBryte™ and the first target market would be the U.S market which would then followed by the European market.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

Non-Dilutive Funding:

Soligenix stock Yesterday on June 9, 2021, announced the receival of $865,000 amount, in non-dilutive funding under the state of New Jersey’s Technology Business Tax Certificate Transfer Program. It’s the eleventh year that SNGX stock is receiving funding for net operating loss. Roughly $6.5 million non-dilutive funding has been received by SNGX stock in this period that has enabled the Soligenix stock to advance its rare disease pipeline.

Recent Developments by SNGX stock:

  • On May 20, 2021, SNGX stock received the Japanese patent titled “Systems and Methods for Producing Synthetic Hypericin” in order to produce the highly purified form of synthetic hypericin
  • About a month ago, the United Kingdom’s(UK’s) Innovative Licensing and Access Pathway (ILAP) had awarded an innovation passport to SNGX stock’s HyBryte™ for the treatment of early-stage cutaneous T-cell lymphoma in adults.
  • In the Annual Conference on Vaccinology Research, the senior vice president, and Chief Scientific Officer, Oreola Donini, Ph.D. of Soligenix stock presented the CiVax™development program in mice and non-human primates (NHPs). CiVax™ is the vaccine against COVID-19.
  • On April 7, the HyBryte™ had been conditionally accepted as SGX301 by the U.S Food and Drug Administration.

Financial View of  SNGX stock:

SNGX stock revenue reduced to $0.1 million for the first three months of 2021 from $0.9 million in the same period of the previous year. Its net loss for the recently reported quarter was $2.4 million, or ($0.06) per share. $1.4 million amount spent on research and development expenses and $0.9 million used in general and administrative expenses by the SNGX stock.SNGX stock’s cash position was  $30.5 million by the end of March 2021.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Conclusion:

So far so good for SNGX stock as far as market sentiment is concerned. Soligenix is deeply focused on the treatment of CTCL via its HyBryte™. The stock is moving forward day by day and can be a good bet for investors in the long run.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Clover Health Investments Corp. (CLOV) stock rises during pre-market. Let’s find out why?

Clover Health Investments Corp. (NASDAQ: CLOV) stock declined by 23.61% at last close while the CLOV stock price gains by 5.73% in the pre-market...

GameStop Inc. (GME) stock plunged during after-hour session. Here’s the update

GameStop Inc. (NASDAQ: GME) stock gained by 0.85% at the last close while the GME stock price declines by 5.21% in the after-hours session....

CynergisTek, Inc. (CTEK) Stock Surges Following Granting of C3PAO Accreditation

CynergisTek, Inc. (CTEK) stock prices were up by a significant 32.26% shortly after market trading commenced on June 9th, 2021, bringing the price per...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam